Sarah Barnes, NP
Family · The Woodlands, TXNPI 1548455132
Payments from drug & device makers
Across 147 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$441
- AstraZeneca$381
- Lilly USA, LLC$368
- Novo Nordisk$333
- Abbott$222
- Jazz Pharmaceuticals Inc.$123
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,008100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 23 | $441 |
| AstraZeneca | 16 | $381 |
| Lilly USA, LLC | 24 | $368 |
| Novo Nordisk | 20 | $333 |
| Abbott | 3 | $222 |
| Jazz Pharmaceuticals Inc. | 1 | $123 |
| Pfizer | 5 | $119 |
| Baxter Healthcare | 3 | $100 |
| Amarin Pharma, Inc. | 4 | $85 |
| Exact Sciences | 5 | $85 |
| Bayer | 4 | $67 |
| Amgen | 3 | $59 |
| Sumitomo Pharma America, Inc. | 4 | $53 |
| Tolmar, Inc. | 3 | $52 |
| Johnson & Johnson | 2 | $39 |
| Inspire Medical Systems, Inc. | 1 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| GSK | 2 | $35 |
| Seqirus USA Inc | 2 | $33 |
| Medtronic | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Shield Therapeutics Inc | 2 | $28 |
| Dexcom, Inc. | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Noven Therapeutics, LLC | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $18 |
| Organon | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Neos Therapeutics, LP | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip System$166
- QULIPTA$125
- FARXIGA$125
- XYWAV$123
How this compares
$3,017 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $39,293 |
| MounjaroTirzepatide | 27 | $27,694 |
| EliquisApixaban | 19 | $20,131 |
| JardianceEmpagliflozin | 11 | $19,594 |
| TrulicityDulaglutide | 13 | $17,297 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $13,510 |
| Rosuvastatin Calcium | 134 | $2,687 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,267 |
| Atorvastatin Calcium | 132 | $1,616 |
| SynthroidLevothyroxine Sodium | 26 | $1,413 |
| Ezetimibe | 29 | $1,222 |
| Omeprazole | 55 | $1,170 |
| Levothyroxine Sodium | 139 | $1,100 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,071 |
| Losartan Potassium | 95 | $931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $368 | $44,99140 claims |
| Novo NordiskOzempic | $333 | $39,29334 claims |
| PfizerEliquis | $119 | $20,13119 claims |
| Boehringer IngelheimJardiance | $18 | $19,59411 claims |
| GSKTrelegy Ellipta | $35 | $13,51015 claims |
| AbbVieSynthroid | $441 | $1,41326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in The Woodlands
- Maggie LavenderThe Woodlands$76K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.